Ramon Colomer

Summary

Country: Spain

Publications

  1. ncbi request reprint Mediterranean diet, olive oil and cancer
    Ramon Colomer
    Medical Oncology, Institut Catala d Oncologia, Hospital de Girona Dr Josep Trueta, Girona, Spain
    Clin Transl Oncol 8:15-21. 2006
  2. ncbi request reprint Gemcitabine in combination with paclitaxel for the treatment of metastatic breast cancer
    Ramon Colomer
    Institut Català d Oncologia Hospital Dr, Josep TruetaGirona, 17007, Spain
    Womens Health (Lond Engl) 1:323-9. 2005
  3. ncbi request reprint Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals
    Teresa Puig
    Girona Biomedical Research Institute IdIBGi and Catalan Institute of Oncology, Dr Josep Trueta University Hospital, Girona, Spain
    Anticancer Res 28:3671-6. 2008
  4. pmc Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells
    Javier A Menendez
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Spain
    BMC Cancer 7:80. 2007
  5. ncbi request reprint Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75
    Teresa Puig
    Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain
    Breast Cancer Res Treat 109:471-9. 2008
  6. doi request reprint A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines
    Jessica Castro
    Laboratori d Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciencies, Universitat de Girona, Campus de Montilivi, Maria Aurèlia Campmany, 69, 17071, Girona, Spain
    Invest New Drugs 30:880-8. 2012
  7. ncbi request reprint An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)
    Laura Ferrer-Soler
    Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
    Int J Mol Med 20:3-10. 2007
  8. ncbi request reprint Gemcitabine and paclitaxel in metastatic breast cancer: a review
    Ramon Colomer
    Medical Oncology Division, Institut Catala d Oncologia, Girona, Spain
    Oncology (Williston Park) 18:8-12. 2004

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Mediterranean diet, olive oil and cancer
    Ramon Colomer
    Medical Oncology, Institut Catala d Oncologia, Hospital de Girona Dr Josep Trueta, Girona, Spain
    Clin Transl Oncol 8:15-21. 2006
    ..Indeed, OA-induced transcriptional repression of HER2 oncogene may represent a novel genomic explanation linking "Mediterranean diet", olive oil and cancer as it seems to equally operate in various types of Her-2/neu-related carcinomas...
  2. ncbi request reprint Gemcitabine in combination with paclitaxel for the treatment of metastatic breast cancer
    Ramon Colomer
    Institut Català d Oncologia Hospital Dr, Josep TruetaGirona, 17007, Spain
    Womens Health (Lond Engl) 1:323-9. 2005
    ..In addition, gemcitabine/paclitaxel is being evaluated in two large adjuvant multicenter studies...
  3. ncbi request reprint Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals
    Teresa Puig
    Girona Biomedical Research Institute IdIBGi and Catalan Institute of Oncology, Dr Josep Trueta University Hospital, Girona, Spain
    Anticancer Res 28:3671-6. 2008
    ..The use of FASN inhibitors has been limited until now by anorexia and weight loss, which is associated with the stimulation of fatty acid oxidation...
  4. pmc Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells
    Javier A Menendez
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Spain
    BMC Cancer 7:80. 2007
    ..e., oleic acid) have been recently described, the anti-breast cancer activities of EVOO non-glyceridic constituents--which consist of at least 30 phenolic compounds--remained to be evaluated...
  5. ncbi request reprint Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75
    Teresa Puig
    Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain
    Breast Cancer Res Treat 109:471-9. 2008
    ..Our results establish EGCG as a potent and specific inhibitor of fatty acid synthesis (FASN), which may hold promise as a target-directed anti-cancer drug...
  6. doi request reprint A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines
    Jessica Castro
    Laboratori d Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciencies, Universitat de Girona, Campus de Montilivi, Maria Aurèlia Campmany, 69, 17071, Girona, Spain
    Invest New Drugs 30:880-8. 2012
    ..In conclusion, PE5 is a cytotoxic ribonuclease that cleaves nuclear RNA and decreases the expression of P-glycoprotein, showing anticancer activity in multidrug-resistant cell lines...
  7. ncbi request reprint An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)
    Laura Ferrer-Soler
    Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
    Int J Mol Med 20:3-10. 2007
    ....
  8. ncbi request reprint Gemcitabine and paclitaxel in metastatic breast cancer: a review
    Ramon Colomer
    Medical Oncology Division, Institut Catala d Oncologia, Girona, Spain
    Oncology (Williston Park) 18:8-12. 2004
    ..Triplet combinations, in which an anthracycline is added to gemcitabine/paclitaxel, are being explored in the metastatic and neoadjuvant settings...